JK
Therapeutic Areas
Genmab Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Epcoritamab | Relapsed/Refractory Large B-cell Lymphoma | Approved |
| Tisotumab vedotin | Recurrent/Metastatic Cervical Cancer | Approved |
| GEN3014 (HexaBody-CD38) | Multiple Myeloma | Phase 3 |
| GEN3013 (DuoHexaBody-CD37xCD3) | Non-Hodgkin Lymphoma | Phase 2 |
| Acasunlimab (DuoBody-PD-L1x4-1BB) | Non-Small Cell Lung Cancer | Phase 2/3 |
| GEN1046/BNT313 (DuoBody-PD-L1x4-1BB) | Solid Tumors | Phase 2 |
| GEN1053 (DuoBody-CD40x4-1BB) | Advanced Solid Malignancies | Phase 1/2 |
| GEN1042 (DuoBody-PD-L1xCD27) | Advanced Solid Tumors | Phase 1/2 |
Leadership Team at Genmab
JV
Jan van de Winkel
President & Chief Executive Officer
AP
Anthony Pagano
EVP & Chief Financial Officer
DS
David Satijn
EVP & Chief Scientific Officer
MC
Michele Corbeil
EVP & Chief Commercial Officer
KD
Karen Dyekjær Hauge
EVP & Chief People Officer
MP
Mats Pettersson
EVP & General Counsel
MG
Michael G. Atieh
Chairman of the Board